- Home
- TKC vs LEGN Comparison
TKC vs LEGN Comparison
Compare TKC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKC
- LEGN
- Stock Information
- Founded
- TKC 1993
- LEGN 2014
- Country
- TKC Turkey
- LEGN United States
- Employees
- TKC N/A
- LEGN N/A
- Industry
- TKC Telecommunications Equipment
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- TKC Telecommunications
- LEGN Health Care
- Exchange
- TKC Nasdaq
- LEGN Nasdaq
- Market Cap
- TKC 5.2B
- LEGN 5.4B
- IPO Year
- TKC 2000
- LEGN 2020
- Fundamental
- Price
- TKC $5.54
- LEGN $36.08
- Analyst Decision
- TKC
- LEGN Strong Buy
- Analyst Count
- TKC 0
- LEGN 12
- Target Price
- TKC N/A
- LEGN $73.36
- AVG Volume (30 Days)
- TKC 847.1K
- LEGN 1.0M
- Earning Date
- TKC 08-13-2025
- LEGN 08-11-2025
- Dividend Yield
- TKC 4.27%
- LEGN N/A
- EPS Growth
- TKC N/A
- LEGN N/A
- EPS
- TKC 0.27
- LEGN N/A
- Revenue
- TKC $4,477,789,455.00
- LEGN $796,838,000.00
- Revenue This Year
- TKC $40.46
- LEGN $70.75
- Revenue Next Year
- TKC $30.01
- LEGN $52.47
- P/E Ratio
- TKC $8.21
- LEGN N/A
- Revenue Growth
- TKC 1.16
- LEGN 74.75
- 52 Week Low
- TKC $5.47
- LEGN $27.34
- 52 Week High
- TKC $7.63
- LEGN $57.54
- Technical
- Relative Strength Index (RSI)
- TKC 35.92
- LEGN 48.36
- Support Level
- TKC $5.47
- LEGN $34.14
- Resistance Level
- TKC $6.20
- LEGN $36.17
- Average True Range (ATR)
- TKC 0.08
- LEGN 1.08
- MACD
- TKC -0.06
- LEGN 0.07
- Stochastic Oscillator
- TKC 8.90
- LEGN 48.67
About TKC Turkcell Iletisim Hizmetleri AS
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.